Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by scarlet1967on Sep 09, 2022 3:24pm
130 Views
Post# 34952985

RE:RE:RE:RE:RE:Down again

RE:RE:RE:RE:RE:Down again

Below is what the MSL is suggesting in order to reach out to the stakeholders. So this was what I was exactly suggesting using the hybrid technology conveniently expanding the range and much more cost/time effective.
The same logic would work when it comes to selling the company to the investors. Behind closed doors meeting with individual investors should be an add on to the whole investor communication not a replacement. The fire chats with concord every darn year is not enough regardless how good the presentation is because it has limited exposure. We can agree or disagree about the prospects of THTX's operations but I don't believe anyone could defend the lack of interest from investors and I blame the low profile marketing/messaging never ending still ongoing strategy they have been implementing for the low volume/illiquidity. If hybrid communication is the new normal teaching/reaching patients/doctors why the heck can't they use it to educate the investors?

<< Previous
Bullboard Posts
Next >>